OLIX PHARMACEUTICALS, INC OliX Pharmaceuticals, Inc Share Price
Equities
A226950
KR7226950004
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,670 KRW | +1.10% |
|
+2.82% | +7.48% |
| Sales 2022 | 9.32B 6.79M 566M | Sales 2023 | 17.06B 12.42M 1.04B | Capitalization | 234B 170M 14.19B |
|---|---|---|---|---|---|
| Net income 2022 | -19.5B -14.19M -1.18B | Net income 2023 | -19.1B -13.91M -1.16B | EV / Sales 2022 | 28 x |
| Net cash position 2022 | 17.88B 13.01M 1.09B | Net Debt 2023 | 13.43B 9.78M 816M | EV / Sales 2023 | 14.5 x |
| P/E ratio 2022 |
-14.3
x | P/E ratio 2023 |
-11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.23% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.10% | ||
| 1 week | +2.82% | ||
| Current month | -5.89% | ||
| 1 month | -5.89% | ||
| 3 months | +8.90% | ||
| 6 months | +18.26% | ||
| Current year | +7.48% |
1 week
14 800.00
16 400.00
1 month
13 870.0016 840.00
Current year
13 170.0018 490.00
1 year
12 900.0025 950.00
3 years
12 900.0053 900.00
5 years
9 800.0061 000.00
10 years
9 800.0061 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dong-Gi Lee
FOU | Founder | 52 | 01/10/01 |
Jun-Hyun Park
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
Young-Hye Baek
BRD | Director/Board Member | 49 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang-Gyoon Kim
BRD | Director/Board Member | 57 | - |
Chang-Soo Yoon
BRD | Director/Board Member | 51 | - |
Dong-Gi Lee
FOU | Founder | 52 | 01/10/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 15,670 | +1.10% | 36,832 |
| 29/24/29 | 15,500 | +1.84% | 35,840 |
| 26/24/26 | 15,220 | -0.59% | 43,715 |
| 25/24/25 | 15,310 | -1.67% | 109,400 |
| 24/24/24 | 15,570 | -2.69% | 75,543 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Companyâs product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +7.48% | 187M | |
| -0.95% | 104B | |
| +6.06% | 97.47B | |
| +5.71% | 22.25B | |
| -13.32% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.23% | 16.36B | |
| +8.58% | 14.39B | |
| +39.58% | 12.37B |
- Stock Market
- Equities
- A226950 Stock
